A new once-a-year injection to prevent HIV has passed an important early safety trial.

Called lenacapavir, the long-acting drug blocks the virus from replicating. Unlike daily PrEP pills, lenacapavir is injected just once a year, slowly releasing into the bloodstream for continuous protection.

Trials showed the drug maintained effective…Read More